Storia in 2 fonti

Migraine biotech makes its debut with $46M to advance preclinical pipeline

Vedana Therapeutics exits stealth with $46M Series A to develop anti-PACAP and bispecific PACAP/CGRP treatments for migraine prevention.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Migraine biotech makes its debut with $46M to advance preclinical pipeline

Vedana Therapeutics exits stealth with $46M Series A to develop anti-PACAP and bispecific PACAP/CGRP treatments for migraine prevention.

originale

biopharmadive.com1 mese fa

A new Westlake-backed biotech takes aim at migraines

Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.

Leggi questa versione → originale

Timeline cronologica

mercoledì 17 giugno 2026·biopharmadive.com
A new Westlake-backed biotech takes aim at migraines
Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine…
mercoledì 17 giugno 2026·endpoints.news
Migraine biotech makes its debut with $46M to advance preclinical pipeline
Vedana Therapeutics exits stealth with $46M Series A to develop anti-PACAP and bispecific PACAP/CGRP treatments for migraine prevention.